Amoy Diagnostics Co

Amoy Diagnostics Co Current Assets

The Current Assets of Amoy Diagnostics Co (300685.SZ) as of Nov 1, 2026 is 44.13 M CNY. In the previous year, Current Assets was 1.80 B CNY — a change of -97.55% (lower).

Current Assets

44.13 MCNY

YoY

-97.55%

Last updated:

Current Assets of Amoy Diagnostics Co is 2025 44.13 M CNY. Current Assets of Amoy Diagnostics Co was 2024 1.80 B CNY. It decreases by -97.55% lower compared to the previous year.

The Amoy Diagnostics Co Current Assets history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Current Assets
Date
Current Assets
Jan 1, 2018
405.60 M CNY
Jan 1, 2019
800.77 M CNY
Jan 1, 2020
1.01 B CNY
Jan 1, 2021
1.20 B CNY
Jan 1, 2022
1.30 B CNY
Jan 1, 2023
1.64 B CNY
Jan 1, 2024
1.80 B CNY
Jan 1, 2025
44.13 M CNY
The Amoy Diagnostics Co Current Assets history
YEARCurrent AssetsYoY
44.13 MCNY-97.55%
1.80 BCNY+9.81%
1.64 BCNY+26.09%
1.30 BCNY+8.68%
1.20 BCNY+18.60%
1.01 BCNY+26.17%
800.77 MCNY+97.43%
405.60 MCNY+26.05%
321.78 MCNY+56.34%
205.82 MCNY+24.12%
165.82 MCNY+129.16%
72.36 MCNY+363.88%
15.60 MCNY-8.11%
16.98 MCNY—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Amoy Diagnostics Co Stock analysis

What does Amoy Diagnostics Co do? Amoy Diagnostics Co., Ltd. generates revenue through the sale of tumor precision molecular diagnostic products, including ADx-ARMS, Super-ARMS, NGS, and FISH testing reagents. These reagents are used for detecting non-small cell lung cancer, colorectal cancer, thyroid cancer, and melanoma in tumor tissue specimens and liquid biopsies. The company also offers data software for gene sequencing data analysis and provides testing services via its medical testing institutions for lung cancer, colorectal cancer, and breast cancer. Revenue streams include reagent sales, software licensing, and diagnostic testing services. The primary customers are medical institutions and healthcare providers requiring tumor molecular diagnostics. The ADx-ARMS product line targets tumor tissue specimen detection, while Super-ARMS serves liquid biopsy applications. NGS and FISH products support comprehensive tumor genetic analysis. Testing services focus on lung, colorectal, and breast cancer diagnostics, catering to hospitals and clinics specializing in oncology. The company’s offerings align with the demand for precise cancer diagnosis and treatment planning. Amoy Diagnostics’ revenue model combines product sales with service-based offerings. Reagent products like ADx-ARMS and Super-ARMS are sold to medical facilities for routine tumor testing. Data software for gene sequencing analysis is licensed to research institutions and hospitals. Testing services through its medical testing institutions provide direct diagnostic solutions for specific cancers, enhancing customer retention through integrated service packages. Amoy Diagnostics Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Amoy Diagnostics Co stock

Current Assets of Amoy Diagnostics Co is 44.13 M CNY in 2025.

Current Assets of Amoy Diagnostics Co changed from 1.80 B CNY to 44.13 M CNY, representing a -97.55% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Current Assets Amoy Diagnostics Co since 2006 – with annual values, charts, and detailed analysis.

Current assets are assets expected to be converted to cash within one year, including cash, receivables, and inventory.

Current Assets's CNY is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Current Assets's Amoy Diagnostics Co historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Amoy Diagnostics Co

All Key Metrics — Amoy Diagnostics Co